TNF and histiocytic sarcoma: Tumor necrosis factor-alpha (TNF-alpha) inhibitors like Adalimumab are one of the first-line therapies approved for use in moderate-to-severe HS, but despite that, there is no consensus on what objective biomarkers can be employed to monitor treatment efficacy.